GlassScriptPhysician profile
Sheri Jamal
NPI 1417245671
$1,485.52
in general payments reported to CMS, 2019-2025
11 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2021: $270 · 2022: $250 · 2023: $306 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $284.99 | 2019-2023 | Diamondback Peripheral |
| Astrazeneca Pharmaceuticals LP | $250.44 | 2021-2022 | |
| Novo Nordisk INC | $221.27 | 2025 | Ozempic |
| Intuitive Surgical, INC. | $135.00 | 2025 | |
| Abbvie INC. | $125.00 | 2022 | |
| Esperion Therapeutics, INC. | $124.99 | 2021 | |
| Lilly USA, LLC | $110.03 | 2025 | Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.55 | 2023 | |
| Glaxosmithkline, LLC. | $98.12 | 2023 | Arexvy |
| Mylan Specialty L.P. | $19.71 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Jamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.